Login to Your Account

Defactinib Moves into De Facto Phase III

By Marie Powers
Staff Writer

Tuesday, September 10, 2013
Verastem Inc. demonstrated that lead candidate defactinib (VS-6063) remains on the fast track by initiating what it called a “registration-directed” trial of the cancer stem cell inhibitor in malignant pleural mesothelioma. The global, double-blind, placebo-controlled COMMAND (Control Of Mesothelioma with MAiNtenance Defactinib) trial plans to enroll 350 to 400 patients, with primary endpoints of progression-free survival (PFS) and overall survival (OS).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription